Search results
Guan YANG, Research Director | Cited by 4,024 | | Read 60 publications | Contact Guan YANG
Li J., Yu K., Pang D., Wang C., Jiang J., Yang S., et al. (2020a). Adjuvant Capecitabine with Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
1 lut 2023 · Background. Regorafenib is an oral multikinase inhibitor and became the first second-line systemic treatment for hepatocellular carcinoma (HCC) following the phase III RESORCE trial. This single-center study retrospectively analyzed the clinical data and follow-up results of patients with recurrent HCC treated with regorafenib and discussed the ...
16 cze 2022 · Here, we present the final overall survival (OS) analysis. In this multicenter, randomized trial, patients were assigned to be treated with concurrent chemoradiotherapy alone (standard therapy, n = 238) or gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiotherapy (n = 242).
24 paź 2023 · Yang Y, Li X, Chen G, et al; CTS-AMI Investigators. Traditional Chinese medicine compound (Tongxinluo) and clinical outcomes of patients with acute myocardial infarction: the CTS-AMI randomized clinical trial.
28 maj 2021 · One prospective multicenter, randomized controlled trial (RCT) involving 284 patients with COVID-19 had shown that LH plus usual treatment could significantly improve the recovery rate (91.5% vs 82.4%) and short the time to symptom recovery (median: 7 days vs 10 days) as compared to usual treatment only. [8]
17 gru 2019 · Ph.D. Candidate at University of Illinois Chicago, Research Assistant and Teaching Assistant.
